Biostax Corp.

About Biostax Corp.

Biostax Corp is a hub-and-spoke biotech development engine focused on powering efficient small-scale med-tech, pharmaceutical, and biotechnology programs. The company aims to shift paradigms in health tech and the treatment of autoimmunity, chronic inflammation, infection, and cancer, with a mission to deliver effective and affordable treatments that enhance quality of life for patients with inflammatory diseases.

Products & Services

Lodonal:An immune system regulator approved in Nigeria for the management of HIV/AIDS. It has shown a 44% increase in CD4 count compared to 11% for standard care, with reduced opportunistic infections.

JKB-122:A small molecule and long-acting TLR4 antagonist with anti-fibrotic, immuno-modulating, and anti-inflammatory properties, demonstrating improvement in liver injuries in preclinical models.

BiostaxRx:A telehealth and inflammaging platform focused on affordable treatments for chronic inflammatory diseases, aiming to reduce inflammation without suppressing the immune system.

CKD Treatment:A late-stage treatment for chronic kidney disease (CKD) management of ESRD complicated by hyperphosphatemia, currently under negotiation for licensing or commercial joint venture.

Smart Contract EHR/Rx Program:An internal program exploring blockchain and distributed ledgers for enhanced security and control over electronic health records and prescriptions, improving patient privacy and regulatory adherence.

Specialties

Med-tech development Pharmaceutical programs Autoimmunity treatment Chronic inflammation management HIV/AIDS treatment Cancer treatment Blockchain in healthcare Telehealth and inflammaging

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Growth Funding Round T: - FT: Growth Funding Round	A: 12000000 MR: - FA: $12 million FAN: 12000000	D: 2023-05-30 FD: 2023-05-30	1 investors

Growth Funding Round Latest

2023-05-30

$12.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Roger Craig Suro

Director

M

Mary Clay Caperton

Director

R

Robert Wilson

VP of Strategy; Director

J

Jane Woods

N

Noreen Griffin

CEO and Founder

K

Kelly Wilson

President

View 4 more team members with Pro

Unlock Full Team Directory

Recent News

Biostax Corp. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised